1. Clinical studies exploring this potential are in progress.

2. In vivo data shows that approximately 2% of BA9 remains on the stent after 28 days. Data on file at Biosensors International.

3. Adapted from Grube E., oral presentation TCT 2010.

BioFreedom™ drug-coated stent is CE Mark approved.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioFreedom, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries.

Not available for sale in the United States and certain other countries.

© 2013 Biosensors International Group, Ltd. All rights reserved.

www.biosensors.com

Ordering Information

<table>
<thead>
<tr>
<th>Stent Diameter (mm)</th>
<th>8</th>
<th>11</th>
<th>14</th>
<th>18</th>
<th>24</th>
<th>28</th>
<th>33</th>
<th>36</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.25</td>
<td>BFR1-2208</td>
<td>BFR1-2211</td>
<td>BFR1-2214</td>
<td>BFR1-2218</td>
<td>BFR1-2224</td>
<td>BFR1-2228</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2.50</td>
<td>BFR1-2508</td>
<td>BFR1-2511</td>
<td>BFR1-2514</td>
<td>BFR1-2518</td>
<td>BFR1-2524</td>
<td>BFR1-2528</td>
<td>BFR1-2533</td>
<td>BFR1-2536</td>
</tr>
<tr>
<td>2.75</td>
<td>BFR1-2708</td>
<td>BFR1-2711</td>
<td>BFR1-2714</td>
<td>BFR1-2718</td>
<td>BFR1-2724</td>
<td>BFR1-2728</td>
<td>BFR1-2733</td>
<td>BFR1-2736</td>
</tr>
<tr>
<td>3.00</td>
<td>BFR1-3008</td>
<td>BFR1-3011</td>
<td>BFR1-3014</td>
<td>BFR1-3018</td>
<td>BFR1-3024</td>
<td>BFR1-3028</td>
<td>BFR1-3033</td>
<td>BFR1-3036</td>
</tr>
<tr>
<td>3.50</td>
<td>BFR1-3508</td>
<td>BFR1-3511</td>
<td>BFR1-3514</td>
<td>BFR1-3518</td>
<td>BFR1-3524</td>
<td>BFR1-3528</td>
<td>BFR1-3533</td>
<td>BFR1-3536</td>
</tr>
<tr>
<td>4.00</td>
<td>BFR1-4008</td>
<td>BFR1-4011</td>
<td>BFR1-4014</td>
<td>BFR1-4018</td>
<td>BFR1-4024</td>
<td>BFR1-4028</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

1. Clinical studies exploring this potential are in progress.

2. In vivo data shows that approximately 2% of BA9 remains on the stent after 28 days. Data on file at Biosensors International.

3. Adapted from Grube E., oral presentation TCT 2010.
Changing the script

Drug Eluting Stents (DES) are proven to reduce the risk of restenosis and improve outcomes for patients with more complex coronary disease. However, in certain patients where there is a requirement to avoid prolonged Dual Anti-Platelet Therapy (DAPT), Bare Metal Stents (BMS) may be preferred. BioFreedom™, as a Drug-Coated Stent (DCS), combines the advantages of both DES and BMS. It delivers an effective anti-restenotic therapy with Biolimus A9™, and may shorten the required DAPT1 regime.

Increasing safety and efficacy

Following a standard deployment, BioFreedom delivers BA9 directly from the abluminal surface to the surrounding vessel wall. After about 28 days, when approximately 98% of the BA9 has been transferred, the BioFreedom stent structure remains acting like a Bare Metal Stent2.

Metal and drug – nothing else

The Biosensors’ SMS surface treatment technology modifies only the abluminal surface of the stent. The resultant surface structure retains the BA9, allowing controlled and progressive release into the surrounding vessel wall after deployment.

Evidence-based approach

CE Mark approval was supported by strong positive data from the BioFreedom First in Man study3. At 12 months, BioFreedom demonstrated non-inferiority to Taxus® Liberté® (pnon-inferiority = 0.001) with a trend towards superior efficacy. Median late lumen loss (LLL) with BioFreedom was 0.17 mm, compared to 0.35 mm in the Taxus® Liberté® group.